BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, ...
Tango Therapeutics reported a net loss of $0.35 per share, which was closely aligned with H.C. Wainwright’s anticipated net loss of $0.33 per share. According to InvestingPro analysis, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results